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Abstract
Cardiovascular disease is the major cause of morbidity and mortality in developed countries and atherosclerosis is the major
cause of cardiovascular disease. Atherosclerotic lesions obstruct blood flow in the arterial vessel wall and can rupture leading to
the formation of occlusive thrombi. Conventional diagnostic tools are still of limited value for identifying the vulnerable arterial
plaque and for predicting its risk of rupture and of releasing thromboembolic material. Knowledge of the molecular and
biological processes implicated in the process of atherosclerosis will advance the development of imaging probes to differentiate
the vulnerable plaque. The development of imaging probes with high sensitivity and specificity in identifying high-risk athero-
sclerotic vessel wall changes and plaques is crucial for improving knowledge-based decisions and tailored individual interven-
tions. Arterial PET imaging with 18F-FDG has shown promising results in identifying inflammatory vessel wall changes in
numerous studies and clinical trials. However, due to its limited specificity in general and its intense physiological uptake in the
left ventricular myocardium that impair imaging of the coronary arteries, different PET tracers for the molecular imaging of
atherosclerosis have been evaluated. This review describes biological, chemical and medical expertise supporting a translational
approach that will enable the development of new or the evaluation of existing PET tracers for the identification of vulnerable
atherosclerotic plaques for better risk prediction and benefit to patients.
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Introduction
Vascular disease is still the leading cause of morbidity
and mortality in the Western world, and the primary
cause of myocardial infarction, stroke, and ischaemia.
Atherosclerosis is a chronic disease of the large arteries
that remains asymptomatic for decades. Arterial wall
changes in the context of atherosclerosis start in child-
hood and vascular lesions enlarge with age and typical-
ly become symptomatic at 50–60 years of age. The
pathobiology of atherosclerosis is complex and lesions
can be generally divided into stable and unstable (also
termed vulnerable) plaques. While stable plaques can
occlude the lumen of the arterial vessel over time, they
can develop plaque erosion. Moreover, plaque rupture
is the dominant initiating event, responsible for 60–
70% of acute coronary syndromes (ACS). It is therefore
important to develop tools that discriminate between
plaques that become vulnerable and plaques that remain
stable but display erosion. State-of-the-art imaging
using novel probes identifying molecular and cellular
processes associated with plaque rupture have the po-
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Plaque biology: cellular and molecular
mechanisms
The process of atherogenesis starts with activation of vascular
endothelial cells, either by vascular shear stress [1] or local
processes [2]. Also platelets can deposit so-called footprints
that direct leucocytes to the vasculature [3]. At the same time
as leucocyte infiltration, a heterogeneous population of vascu-
lar smooth muscle cells (VSMCs) is established in the
subintimal space [4]. It has been shown that VSMCs are im-
portant in health and disease [5]. The pool of intimal VSMCs
in the atherosclerotic lesion might arise from the infiltration of
haematopoietic stem cells that differentiate locally into
VSMCs [6]. However, more recently, VSMC lineage tracing
in apoE-null mice has shown that a majority of atherosclerotic
lesion cells are derived fromVSMCs from the vasculature [7].
The accumulation of low-density lipoproteins (LDL), that be-
come oxidized, promotes macrophages to take up these rem-
nants via their scavenger receptor. These foam cells are the
starting point of the so-called fatty streak. In response to these
proinflammatory macrophages, more VSMCsmigrate into the
vascular intima producing a fibrous cap around the xanthomal
lesion. In addition, the proinflammatory macrophages attract
more macrophages which further fuel the inflammatory vas-
cular process. Due to hypoxia in the core of the atherosclerotic
plaque, a necrotic core develops and intraplaque neovascular-
ization is upregulated in response. Finally, cellular debris cal-
cifies and the amount of calcification is a measure of the ath-
erosclerotic burden [8].
Many features have been linked to plaque vulnerability
including perivascular inflammation, large necrotic core, thin
fibrous cap, microcalcifications, intraplaque haemorrhage,
neoangiogenesis and hypoxia [9]. A thin fibrous cap is the
result of degradation of collagen by metalloproteinase derived
from activated macrophages. The rupture of an atherosclerotic
plaque usually takes place at the shoulders of the plaque where
the cap is thinnest. A large necrotic core and increased angio-
genesis are a consequence of inflammation and hypoxia.
Endothelial cells of intraplaque (micro)vessels express adhe-
sion molecules favouring leucocyte recruitment. These angio-
genic vessels are immature and fragile and due to extravasa-
tion of leucocytes further contribute to atherosclerosis pro-
gression. Inflammation has been linked to both apoptosis
and calcification [10, 11], and oxidative stress has been shown
to be responsible for VSMC calcification [12, 13].
Vascular calcification was long considered a passive pro-
cess not amenable to intervention. A paradigm shift camewith
the discovery that so-called Gla proteins are involved in the
regulation of mineral deposition in the vasculature [14].
Vascular calcification is now considered an active process
with cellular and humoral contributions which plays an im-
portant role in cardiovascular morbidity and mortality [15].
The discovery that vitamin K-dependent proteins are
inhibitors of vascular calcification has advanced our mecha-
nistic understanding of the calcification process and opened
novel avenues for diagnosis and treatment [16].
Vascular calcification comes in different flavours: calcifi-
cation can occur in the vascular intima as well as in the media
and it may have different shapes and sizes. Recent data sug-
gest that microcalcification can have a destabilizing effect on
atherosclerotic plaques [2, 17], in contrast to the hypothesis
tha t large ca lc i f ica t ions are p laque-s tab i l iz ing .
Microcalcification arises from dedifferentiated VSMCs that
start secreting extracellular vesicles, that in the extracellular
space form the nidus for calcification [18]. These
microcalcifications, which are undetectable by conventional
imaging, increase the local stress inside the thin fibrous cap
twofold and thus increase the likelihood of rupture [19]. These
m i c r o c a l c i f i c a t i o n s w i l l e v en t u a l l y r e s u l t i n
macrocalcification as a product of osteogenic action by
osteocyte-like and chondrocyte-like cells inside the plaque.
Novel imaging tools allow the course of microcalcification
to be followed [20]. In a rodent model of atherosclerosis,
macrophage infiltration in early atherosclerotic plaques has
been shown to colocalize with calcification. Indeed,
microcalcifications that are phagocytosed bymacrophages po-
larize towards the proinflammatory M1 phenotype [21].
Effective screening to identify the vulnerable plaque is still
lacking. This is largely due to the absence of insight into the
pathophysiology of vulnerable plaque and thus the lack of
cost-effective interventions. Since the genesis of
microcalcification is considered one of the earliest precursor
processes in the formation of vulnerable plaque [2, 22], ade-
quate early intervention and prevention are possible.
Therefore, it is important to understand the factors that drive
microcalcification as well as the underlying mechanisms.
However, the vast majority of so-called ‘vulnerable’ plaques
do not exhibit clinical ‘instability’ and indeed seldom induce
ACS [23]. Due to effective treatment, i.e. with statins, lesions
became more stable. These lesions underlying superficial ero-
sion do not have thin fibrous caps, have fewer inflammatory
cells and lack a large lipid core. Rather they are more collagen-
rich lesions and have more calcification, but they are still
prone to form occlusive thrombi [23]. These considerations,
taken together, indicate the high promise of vascular calcifi-
cation as a new target for diagnosis and intervention in cardio-
vascular diseases, with an urgent need to translate experimen-
tal findings into adequate diagnostic, preventive and therapeu-
tic solutions.
18F-FDG PET imaging of atherosclerosis
The strength of nuclear medicine is its ability to provide quan-
titative information at a functional level, such as the density of
a specific receptor or the metabolic activity of a plaque.
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Nuclear imaging is based on radiolabelled biomarkers with a
signal sensitivity in the picomolar range, which compares
favourably with both MRI and especially CT, both of which
have sensitivities up to a trillion times lower [21, 22]. PET
images are derived from the detection of positron-emitting
radionuclides labelling biochemical and metabolic substrates.
The radionuclide is administered intravenously and circulates
within the body. This allows time for the tracer to accumulate
at the site of interest. To obtain a favourable target-to-
background ratio, the radionuclide should be cleared from
the blood quickly. The high sensitivity of PET coupled with
the favourable resolution of CT and MRI, as already achieved
in PET/CT and PET/MRI hybrid imaging systems provides
valuable information about the localization of the acquired
signal [24–26].
To obtain good quality images a high target-to-background
ratio is mandatory for vascular PET imaging, for which the
radiotracer must show high uptake in the target and preferably
also rapid clearance from the bloodstream. Due to the small
size of plaques, a high background activity mainly in the
blood would severely impair the quality of PET images.
Furthermore, coronary artery imaging presents special prob-
lems. Cardiac and respiratory movement, myocardial tracer
uptake, especially of 18F-FDG, and the small size (3 to
4 mm) of the coronary arteries may impair and even preclude
imaging of the coronary arteries by PET. Whereas motion
artefacts can be reduced by using modalities such as cardiac
gating, especially with the relatively slow PET data acquisi-
tion, suppression of the unwanted myocardial 18F-FDG up-
take might be achieved using a different available dietary pro-
tocols [21, 22].
The radioactive tracer most commonly used clinically for
PET imaging is 18F-FDG. 18F-FDG is mainly used for onco-
logical studies and is well-established for the diagnosis and
staging of malignant tumours and the monitoring of therapy
response. The tracer is transported into cells by glucose trans-
porters and is phosphorylated by hexokinase to 18F-FDG-6-
phosphate that is not further metabolized [27]. The degree of
cellular 18F-FDG uptake is related to the metabolic rate and
the number of glucose transporters [28]. Therefore, increased
18F-FDG uptake in malignant tumour cells is partly due to an
increased number of glucose transporters found in these cells.
An increased number of glucose transporters is also found in
activated inflammatory cells, such as macrophages.
Additionally, the affinity of glucose transporters for
deoxyglucose is apparently increased in these cells under in-
flammatory conditions by various cytokines and growth fac-
tors [27, 29]. However, potential competition between 18F-
FDG and nonradioactive stable glucose for uptake in metabol-
ically active cells (for example, inflammatory) might affect the
imaging results in patients with high prescan glucose levels.
Furthermore, an excess of unlabelled glucose and the action of
insulin may increasingly affect the accumulation of 18F-FDG
due to saturation of the glucose transporters [30, 31]. In addi-
tion, increases in plasma insulin levels result in translocation
of the GLUT-4 transporters from an intracellular pool to the
plasma membrane [32, 33]. This may enhance the uptake of
18F-FDG in myocardial and skeletal muscle, which in turn
could significantly impair the quality and interpretability of
18F-FDG PET scans. This issue needs to be kept in mind
particularly in patients with diabetes who are frequently af-
fected by atherosclerosis, as diabetes is one of the main car-
diovascular risk factors [34–39].
18F-FDG PET in preclinical studies
Methodological considerations of preclinical PET
imaging of atherosclerosis
The availability of dedicated small-animal PET as well as
hybrid PET/CT and now PET/MRI systems offers and facili-
tates the widespread use of preclinical PET imaging of athero-
sclerosis. This is crucial not only to understand the pathophys-
iology of the development and progression of atherosclerosis
in vivo, but also to evaluate newly developed PET tracers for
functional imaging of atherosclerosis. This also applies to
PET tracers originally introduced into clinical routine for other
indications, for example 68Ga-DOTATATE for the imaging of
neuroendocrine tumours and 18F-fluorocholine (18F-FCH) for
the (former) imaging of prostate cancer disease. To investigate
their ability to enhance the visibility of atherosclerosis on PET
they can be tested in vivo in a preclinical setting and correlated
with histology for imaging distinct parts of the disease
process.
The most common tool used in preclinical studies of ath-
erosclerosis is still genetically modified mouse models [40].
Using these mouse models has provided a deep insight into
the pathophysiological mechanisms in atherosclerosis despite
obvious and well-known differences between human and mu-
rine atherosclerosis – including vessel architecture, plaque
composition and stability [40–42]. The currently available ge-
netically modified mouse models are suitable for initial eval-
uation of new PET tracers for atherosclerosis imaging.
However, several steps of the human atherosclerotic disease
process still cannot be covered by the available preclinical
mouse models, impairing comparison with and translation to
the human situation [40]. Therefore, attempts are being made
to develop more appropriate mouse models to study plaque
rupture [43]. Suggested models are brachiocephalic plaque
disruption in aged apoE-null mice fed a high fat diet [44],
plaque rupture in the brachiocephalic artery in mice fed a high
fat diet and receiving angiotensin II [45] or warfarin [46],
transfection of mice with haematopoietic stem cells with over-
expression of matrix metalloproteinase 9 (MMP-9) [47] or
urokinase plasminogen-activator (uPA) in macrophages [48],
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or collar placement on the carotid artery in apoE-null mice
with stimulation with lipopolysaccharide and phenylephrine
[49]. The suitability of these mouse models for mimicking
atherosclerosis in humans more closely has to be proven in
the near future.
Another approach to overcoming the shortcomings of ath-
erosclerotic mouse models is the use of larger species for
preclinical imaging such as rabbit or porcine models.
Because of their greater size, rabbit arteries are large enough
for more detailed analysis of arterial plaque components by
PET, MRI and CT. This also allows serial imaging analysis in
the context of interventional studies testing for strategies in
plaque stabilization and/or regression, for example by apply-
ing lipid-lowering drugs. The size of rabbit arteries also al-
lows the placement of, for example, endovascular stents, a
model which can be used for the assessment of re-
endothelialization of vascular therapeutic devices measured
using PET [50, 51].
Recently, a rabbit model of vulnerable atherosclerotic
plaques has been introduced, and seems to overcome the ab-
sence of an appropriate mouse model for this purpose. This
model consists of placing a vascular (arterial) injury in rabbits
receiving a hyperlipidaemic diet [52–54]. Of all preclinical
models representative of the clinical situation, porcine models
may be the best option for the investigation of atherosclerosis.
Pigs not only exhibit vessel wall architecture similar to that in
humans, but also respond in the same way as humans to ex-
posure to oxidized LDL. Furthermore, they develop atheroma
lesions in response to insulin resistance and also develop vul-
nerable atherosclerotic plaques [43, 55, 56]. Besides the path-
ophysiological similarities between porcine and human
plaques, another advantage of using porcine atherosclerosis
models is related to the size of the porcine vessels, which are
sufficiently large to enable the evaluation of not only small
vessels such as the coronary arteries but also neointimal hy-
perplasia and neovascularization. Furthermore, PET imaging
of smaller arterial structures is also facilitated by the larger
vessel size, which is crucial because of the rather low spatial
resolution of PET compared with that of CT and MRI [57].
From a technical point of view, the combination of nonin-
vasive imaging methodologies such as PET and CT or MRI
facilitates efforts to develop new preclinical models for ath-
erosclerosis imaging. Such models would allow not only eval-
uation of the functional aspects of a ‘vulnerable’ atheroscle-
rotic plaque with PET, but also determination of the precise
location as well as morphological parameters of atherosclerot-
ic lesions with CT or MRI.
Unquestionably, animal models are indispensable to the
elucidation of the molecular mechanisms that underlie human
atherosclerosis and plaque vulnerability. Each animal model
has its own advantages and disadvantages concerning cost and
the possibility of modulating cell and cellular factors that in-
fluence the atherogenic process. In order to answer a research
question properly, the correct choice of animal model is
decisive.
Preclinical imaging studies with 18F-FDG PET
Preclinical studies indicating that 18F-FDG PET might have a
role in imaging atherosclerosis have been performed in
cholesterol-fed rabbits. A positron-sensitive fibre-optic probe
placed in contact with the arterial intima was able to detect
high 18F-FDG uptake in atherosclerotic segments of the iliac
artery [58]. That 18F-FDG is able to identify vulnerable plaque
was demonstrated in a rabbit model of atherosclerosis in
which plaque rupture was promoted by venom injection.
Aziz et al. found that only the aortic plaques with the highest
preinjection 18F-FDG uptake progressed to rupture and throm-
bosis [59]. The suitability of 18F-FDG PET for the investiga-
tion of therapeutic interventions was shown in a rabbit model
of atherosclerosis in which there was a significant reduction in
18F-FDG uptake after 3 months of therapy with a lipid-
lowering antioxidant agent [60].
Imaging atherosclerosis with 18F-FDG PETalso has poten-
tial drawbacks. 18F-FDG was administered intravenously to
atherosclerotic LDLR/ApoB48 mice and control mice and the
ex vivo distribution in frozen aortic sections was measured by
digital autoradiography [61]. Additionally, in vitro uptake of
18F-FDG in human atherosclerotic arteries was also examined.
Unexpectedly, significant 18F-FDG uptake was found in the
vicinity of calcified structures atherosclerotic plaques in mice.
This uptake seemed to bemore prominent than in noncalcified
atherosclerotic plaques. The in vitro studies of atherosclerotic
human arteries showed similar results with marked uptake of
18F-FDG in the calcifications but not in other structures of the
artery wall.
To overcome the limitations of 18F-FDG PET imaging of
atherosclerosis, PET tracers originally introduced for imaging
other indications (such as oncological or neurological disor-
ders) have been used in numerous preclinical studies to eval-
uate potential candidates for screening of vulnerable athero-
sclerotic plaque. In these studies, different PET tracers were
used to those used in preclinical models; for example, 18F-
FCH and 18F-labelled analogues of CGS 27023A for imaging
MMPs, and 124I-labelled platelet glycoprotein VI (124I-GPVI)
for imaging thrombosis at sites of atherosclerotic lesions
[62–65].
18F-FDG PET imaging in clinical studies
Arterial 18F-FDG uptakewas first noted in the aorta of patients
undergoing 18F-FDG PET for cancer imaging [66]. It was also
shown that the amount of 18F-FDG uptake increased with age
and was higher in patients with cardiovascular risk factors [29,
67, 68]. Supported by cell culture work, 18F-FDG uptake in
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the arterial wall can probably be attributed to uptake in plaque
macrophages. These studies demonstrated that increased oxi-
dative metabolism and glucose use in response to cellular
activating agents is accompanied by a dramatic increase in
18F-FDG uptake in both leucocytes andmacrophages [36, 69].
Following the dedicated preclinical studies of the use of
18F-FDG PET for imaging atherosclerosis, Rudd et al. per-
formed one of the first clinical studies of atherosclerosis im-
aging with 18F-FDG PET in patients with transient ischaemic
attack [70]. The patients were scanned shortly after symptom
onset and a significantly higher 18F-FDG uptake (almost 30%)
was seen in symptomatic carotid plaques than in the asymp-
tomatic artery [70]. This indicates the feasibility of 18F-FDG
PET for the imaging of inflammation in the aorta, and in
peripheral and vertebral arteries [71–73]. The relationship be-
tween uptake of 18F-FDG and inflammation has been demon-
strated using histology linking 18F-FDG uptake with the num-
ber of macrophages in arterial specimens [74, 75]. In addition
to findings indicating 18F-FDG uptake as a marker of arterial
inflammation, preliminary studies have indicated that 18F-
FDG has the potential to predict plaque rupture as well as
clinical events. Regarding the predictive value of 18F-FDG
PET, in a study includingmore than 2,000 patients with cancer
disease, Paulmier et al. found that, compared with patients
with a low arterial 18F-FDG uptake, patients with the highest
18F-FDG uptake were more likely to have either a previous
vascular event or to experience an event during the 6 months
after PET imaging [76]. Furthermore, the short-term interscan
reproducibility of 18F-FDG PET in the imaging of atheroscle-
rosis has been shown to be excellent for the carotid artery,
aorta and peripheral arteries [69, 71, 73, 77]; this is an impor-
tant finding mainly for the use of 18F-FDG PETas an endpoint
parameter in intervention studies.
Despite the widespread use of 18F-FDG PET/CT in cardio-
vascular disease, nonspecific uptake of the tracer is undoubt-
edly the most important drawback of the use of 18F-FDG for
imaging atherosclerosis [54]. 18F-FDG is nonspecifically tak-
en up by almost all human tissues and organs to a certain
degree. 18F-FDG uptake analysis in arterial and/or venous
vessels is therefore hampered by significant spill-over of trac-
er signal from closely neighbouring structures; for
example, 18F-FDG uptake in the thyroid gland during carotid
PET imaging or myocardial 18F-FDG uptake during PET im-
aging of the thoracic aorta or coronary arteries. Furthermore,
pathologically increased 18F-FDG uptake in structures close to
the target vessel further impair 18F-FDG uptake analysis in
atherosclerotic plaques; for example, inflamed cervical lymph
nodes close to the carotid arteries. More importantly, signifi-
cant 18F-FDG uptake has been found in atherosclerosis-prone
mice in the vicinity of calcified structures in plaques, and this
has been confirmed in in vitro studies of atherosclerotic hu-
man arteries that showed marked binding of 18F-FDG to cal-
cifications but not to other structures of the artery wall [61].
On the basis of these findings taken together, studies to eval-
uate new or already existing PET tracers currently used for
indications other than atherosclerosis are warranted. These
PET tracers might be more specific and possibly more sensi-
tive for detecting high-risk vulnerable plaques.
Beyond 18F-FDG: PET radiotracers for target
identification in atherosclerosis
18F-Fluorocholine
18F-FCH was introduced several years ago for imaging the
brain and for diagnosis of prostate cancer disease [78, 79].
Choline is taken up into cells by specific transport mecha-
nisms and phosphorylated by choline kinase. Increased cho-
line uptake has been shown both in tumour cells and in acti-
vated macrophages [80, 81]. Previously published studies
demonstrated enhanced 18F-FCH uptake after soft tissue in-
fection or acute cerebral radiation injury that correlated well
with macrophage accumulation as part of an inflammatory
reaction [82, 83]. In a murine model of atherosclerosis,
ex vivo imaging with 18F-FCH provided better identification
of plaques than imaging with 18F-FDG, indicating that this
tracer may be a promising candidate for imaging plaques in
patients [62].
The first feasibility study of the use of 18F-methylcholine
(18F-FMCH) PET for imaging arterial plaques was performed
in five patients undergoing imaging for prostate cancer [84].
Morphological classification of vessel wall alterations in the
abdominal aorta and the common iliac arteries included struc-
tural wall alterations without additional calcifications, struc-
tural wall alterations associated with calcifications, and solely
calcified lesions. The use of 18F-FMCH was shown to be
feasible for in vivo imaging of structural vessel wall alter-
ations in humans, which provided the basis for several subse-
quent studies on vascular 18F-FCH PET imaging [84].
Confirming these results, Kato et al. reported the results of a
retrospective study of the use of 11C-choline PET imaging of
vascular plaques in 93 patients with prostate cancer [85]. 11C-
Choline uptake was found in 95% of the patients and calcifi-
cation in 94% throughout all vessel segments. However,
colocalization of choline uptake with calcifications was found
in only 6% of the patients. Furthermore, less than 1% of cal-
cification sites showed increased radiotracer uptake. Thus, in
concordance with the previous data, 11C-choline uptake and
calcification were found to be only rarely colocalized [84, 85].
Because of the high uptake of 11C-choline and the high pro-
portion of calcifications without colocalization, 11C-choline
potentially provides information about atherosclerotic plaques
independent of calcification measurement [85].
In a retrospective study including 60 patients with prostate
cancer examined with whole-body PET/CT using 18F-
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fluoroethylcholine (18F-FEC), uptake in the wall of the as-
cending and descending aorta, aortic arch, abdominal aorta,
and both iliac arteries was measured, and the sum of calcified
plaques (CPsum) in these vessels was also calculated. These
data were correlated with the presence of cardiovascular
risk factors and occurrence of prior cardiovascular events
[86]. CPsum was significantly correlated with cardiovas-
cular risk factors. However, no significant association
was found between 18F-FEC uptake in large vessels
and atherosclerotic plaque burden, in contrast to the stud-
ies by Bucerius et al. and Kato et al. [84, 85]. It is
noteworthy that the lack of an association between cho-
line uptake and calcified arterial plaque burden reported
by Förster et al. was also seen in the two previous stud-
ies of vascular choline PET imaging [84–86]. Recently, a
prospective study including ten consecutive stroke pa-
tients with ipsilateral carotid artery stenosis of >70%
was reported. Patients were scheduled for carotid endar-
terectomy and underwent PET for the assessment of the
maximum 18F-FCH uptake in the ipsilateral symptomatic
carotid plaques and contralateral asymptomatic carotid
arteries [87]. The PET imaging results were correlated
with histological evaluation of the macrophage content
in all carotid endarterectomy specimens as the CD68+
staining percentage per whole plaque area and as the
maximum CD68+ staining percentage in the most in-
flamed section/plaque. A strong correlation between
18F-FCH uptake in the carotid atherosclerotic plaque
and degree of macrophage infiltration indicates that 18F-
FCH PET is a promising tool for the evaluation of vul-
nerable plaques [87].
68Ga-DOTATATE
68Ga-DOTATATE PET imaging has gained widespread ac-
ceptance in clinical routine for imaging somatostatin
receptor-positive neuroendocrine tumours. These somatostat-
in receptors of subtype 2 are also expressed by macrophages
and can therefore be detected by 68Ga-DOTATATE PET im-
aging [88–90]. One advantage compared to 18F-FDG is that
68Ga-DOTATATE does not show physiological uptake in the
myocardium. Therefore, besides imaging of the carotid arter-
ies (Figs. 1 and 2) and aorta, imaging of the coronary arteries
with 68Ga-DOTATATE seems feasible, independent of the still
unresolved methodological issues such as inappropriate spa-
tial and temporal resolution related to coronary PET imaging.
Rominger et al, determined the uptake of 68Ga-DOTATATE in
the left anterior descending artery (LAD) in a series of 70
oncological patients undergoing 68Ga-DOTATATE whole-
body PET/CT [90]. 68Ga-DOTATATE uptake was detectable
in the LAD of all patients and correlated significantly with the
presence of calcified plaques and prior vascular events.
Calcified plaque burden was also correlated with prior
vascular events and with patient age and the presence of hy-
pertension. Therefore, the use of 68Ga-DOTATATE seems fea-
sible for the imaging of vulnerable atherosclerotic plaque in
coronary arteries.
Li et al. compared the uptake of 68Ga-DOTATATE and 18F-
FDG in eight arterial segments in 16 patients with neuroendo-
crine tumours or thyroid cancer who underwent PET imaging
Fig. 1 Fused PET/CT and CT images show 68Ga-DOTATATE uptake in
the left common carotid artery close to the bifurcation (arrows), which is
visually and semiquantitatively higher than in the right carotid artery,
indicating increased inflammatory changes in the left carotid artery
Fig. 2 Fused PET/CT images show only slight 68Ga-DOTATATE uptake
at the bifurcation of the left carotid artery with, on the CT images, as part
of the fused PET/CT images, visible calcification (arrow). Combined
molecular (68Ga-DOTATATE PET) and morphological imaging (CT)
indicates more stable, chronic arterial vessel wall changes
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with both tracers for staging or restaging [91]. 68Ga-
DOTATATE uptake in all large arteries was correlated signif-
icantly with the presence of calcified plaques, the presence of
hypertension, age and uptake of 18F-FDG. In contrast, 18F-
FDG uptake was significantly correlated only with the pres-
ence of hypertension. Of the 37 sites with the highest focal
68Ga-DOTATATE uptake, 16 (43.2%) also had focal 18F-FDG
uptake. In contrast, of 39 sites with the highest 18F-FDG up-
take, only 11 (28.2%) showed colocalization with 68Ga-
DOTATATE uptake. Thus, 68Ga-DOTATATE uptake seems
to be more strongly associated with known risk factors of
cardiovascular disease than 18F-FDG uptake. Interestingly, fo-
cal uptake of 68Ga-DOTATATE was shown not to be
colocalized with 18F-FDG uptake in a significant number of
lesions [91]. The disparity between these two tracers seems to
reflect the fact that 68Ga-DOTATATE is a specific macrophage
marker in atherosclerosis in contrast to 18F-FDG, whereas 18F-
FDG provides a nonspecific measurement of glucose metab-
olism of cells within the atherosclerotic plaque. Furthermore,
68Ga-DOTATATE might offer a more ‘focal’ approach in im-
aging atherosclerotic lesions than 18F-FDG [92].
64Cu-DOTATATE can also be used in combination with
vascular hybrid PET/MRI imaging to evaluate atherosclerosis
in the carotid arteries [93]. Significantly higher 64Cu-
DOTATATE uptake was found in symptomatic plaques than
in the contralateral carotid artery. In a subsequent analysis, a
total of 62 plaque segments were assessed for gene expression
of selected markers of plaque vulnerability. A univariate anal-
ysis comparing these results with 64Cu-DOTATATE uptake
in vivo showed that CD163 and CD68 gene expression was
correlated weakly although significantly with the mean stan-
dardized uptake values in the PET scans. In a multivariate
analysis CD163 was correlated independently with the 64Cu-
DOTATATE uptake, whereas CD68 was not, indicating that
64Cu-DOTATATE-PET might detect alternatively activated
macrophages.
18F-Sodium fluoride
18F-NaF is a positron-emitting bone-seeking agent which re-
flects blood flow and remodelling of bone. Therefore, 18F-
NaF has received attention in the field of imaging alterations
in calcification in atherosclerotic plaques. In a feasibility
study, Derlin et al. retrospectively evaluated imaging data
from 75 patients undergoing whole-body 18F-NaF PET/CT
[94]. 18F-NaF uptake was observed at 254 sites in 57 patients
(76%) and calcification was observed at 1,930 sites in 63
patients (84%). Colocalization of radiotracer accumulation
and calcification was observed in 223 areas of uptake (88%).
Interestingly, only 12% of all arterial calcification sites
showed increased radiotracer uptake, indicating that 18F-NaF
might be much more sensitive in detecting so-called spotty
calcifications than CT. The same group investigated 18F-NaF
uptake in the common carotid arteries of neurologically
asymptomatic patients with cardiovascular risk factors and
carotid calcified plaque burden [95]. They included 269 on-
cological patients who underwent 18F-NaF PET/CT. 18F-NaF
uptake in the common carotid arteries was observed at 141
sites in 94 patients (34.9%) and showed colocalization with
calcification in all atherosclerotic lesions. 18F-NaF uptake was
significantly associated with age, male sex, and the presence
of hypertension and hypercholesterolaemia. The presence of
calcified atherosclerotic plaques was correlated significantly
with these risk factors and also with diabetes, history of
smoking and prior cardiovascular events. Furthermore, a high-
ly significant correlation was found between 18F-NaF uptake
and the number of cardiovascular risk factors.
Intriguing results of a prospective clinical trial of vascular
18F-NaF PET imaging have been reported [96]. Both 18F-NaF
and 18F-FDG PET/CT and invasive coronary angiography
were performed in 40 patients with myocardial infarction
and 40 patients with stable angina. 18F-NaF uptake was com-
pared with histology in carotid endarterectomy specimens
from patients with symptomatic carotid disease, and with in-
travascular ultrasonography in patients with stable angina. In
37 patients (93%) with myocardial infarction, the highest cor-
onary 18F-NaF uptake was seen in the culprit plaque.
Interestingly, in contrast to the findings for 18F-NaF (which
is not physiologically taken up by the myocardium), coronary
18F-FDG uptake was commonly obscured by myocardial up-
take and where discernible, there were no differences between
culprit and nonculprit plaques. At the sites of carotid plaque
rupture, significant 18F-NaF uptake was observed, and was
associated with histological evidence of active calcification,
macrophage infiltration, apoptosis and necrosis [96].
Coronary atherosclerotic plaques with focal 18F-NaF uptake
were seen in 18 patients (45%) with stable angina.
Intravascular ultrasonography in these patients revealed more
high-risk features in plaques with increased 18F-NaF uptake,
such as positive remodelling, microcalcification and necrotic
core, than in plaques without 18F-NaF uptake. These promis-
ing results indicate, that 18F-NaF PET imaging might be a
sensitive method for identifying and localizing ruptured and
high-risk coronary plaques.
Irkle et al. reported intriguing results of an extensive anal-
ysis of vascular 18F-NaF binding using electron microscopy,
autoradiography, histology and preclinical and clinical PET/
CT [97]. 18F-NaF was found to directly adsorb to calcified
areas in mineralized vascular tissue and this binding was
found to be highly specific, as 18F-NaF uptake was seen solely
in calcification with no localization in other soft tissues.
Furthermore, 18F-NaF uptake was found to be highly depen-
dent on the surface area of the calcification. The tracer was
only absorbed to the outer layer of calcification regions, sug-
gesting that 18F-NaF only detects active mineralization [97].
Fiz et al. found that 18F-NaF hot spots were present in
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atherosclerotic plaques in 86% of patients at sites without
visible calcification on CT [98]. These findings suggest that
18F-NaF localizes at sites of microcalcification that are invis-
ible on CT at the current clinical resolution, and strongly sug-
gest that microcalcifications are a cause of atherosclerosis
rather than a consequence [2]. Additionally, mice treated with
warfarin (vitamin K antagonist) showed 18F-NaF hotspots in
the abdominal aorta within 2 weeks of treatment, indicating
that drug-induced inactivation of vitamin K-dependent pro-
teins results in early active mineralization (unpublished data;
Fig. 3).
The characteristic properties of 18F-NaF as a highly specif-
ic ligand for the detection of pathologically high-risk
microcalcification, and therefore early unstable atherosclerotic
disease, makes it a highly valuable tracer for noninvasive
evaluation in human high-risk atherosclerotic plaques.
The future: novel PET radiotracers
18F-Aluminium labelling
For routine PET imaging, 18F is today the best radionuclide
with a half-life (T½) of 109.8 min and low β
+ energy
(0.64 MeV). Compared with other short-lived radionuclides,
such as 11C (T½ = 20.4 min), its half-life is long enough to
allow synthesis and imaging procedures to be extended over
hours, enabling kinetic studies and high-quality metabolite
and plasma analysis.
Efficient 18F labelling of peptides and proteins is often a
multistep process involving labelling and purification of a
prosthetic group (synthon) and subsequent conjugation of
the 18F-labelled synthon to the peptide/protein with or without
activation. If necessary, the 18F conjugate is purified by a final
purification step. Over the years, a variety of prosthetic groups
have been developed ranging from amine-reactive groups
such as N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB)
[ 9 9 ] t o c h emo s e l e c t i v e g r o u p s , f o r e x amp l e
4-[18F]fluorobenzaldehyde and 18F-FDG [100, 101], that react
with an aminooxy-modified or hydrazine-modified peptide.
A special prosthetic group approach that has been explored
in 18F labelling chemistry is click chemistry methodology.
Click chemistry appears to be an effective method for
radiolabelling peptides and proteins, because the click reac-
tion is fast, bioorthogonal, chemoselective and regioselective,
and results in relatively high yields and can be performed in
aqueous media. This copper(I)-catalysed azide-alkyne cyclo-
addition reaction has been exploited in radiopharmaceutical
chemistry by several research groups [101–106]. A variant
of the copper(I)-catalysed click reaction is the copper-free
click reaction that does not require the use of the cytotoxic
metal. Reactions of electron-deficient tetrazines with ring-
trained trans-cyclooctenes or norbenes have been investigated
[107–111]. Click reactions, Cu(I)-catalysed and copper-free,
have been shown to be powerful and versatile reactions for the
synthesis of 18F-labelled peptides and proteins.
Although there are a variety of possible methods for intro-
ducing 18F into a peptide or protein, a major drawback of the
18F-labelling methods described above is that they are
labourious (require azeotropic drying of the fluoride and mul-
tiple purification steps) and thus time-consuming. In search of
a kit-based 18F-labelling method, new 18F-labelling strategies
based on fluorine–silicon [112–115], fluorine–boron
[116–118], and fluorine–phosphorus [119] have been devel-
oped. A straightforward chelator-based approach to labelling
peptides and proteins with 18F was proposed in 2009 by
McBride et al. [120]. They demonstrated that it is feasible to
radiofluorinate compounds by first creating a stable 18F-Al
complex which can subsequently be attached to the compound
via a chelator. The 18F-Al labelling procedure has recently
been significantly improved by optimizing chelators and la-
belling conditions [121]. This 18F-labelling technique has
been demonstrated to be applicable to many peptides and pro-
teins and has proved to be a versatile approach, especially for
peptides and proteins that are not stable under harsh labelling
conditions.
Fig. 3 Sprague Dawley rats at 10–12weeks of age were subjected to either
a chow diet or a chow diet supplemented with warfarin (3 mg/g + 1.5 mg/
g K1) for 2 weeks. a b 18F-NaF PET/CT images obtained after 2 weeks in
animals on the chow diet (a) and in animals on the warfarin-supplemented
chow diet (b): animals on the supplemented diet show uptake in the
descending aorta indicating hotspots of calcification which are not seen
in the animals on the chow diet. c Ex vivo histochemical Alizerin Red
staining of aortic tissue reveals calcification of the vasculature
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Peptide-based and protein-based PET radiotracers
18F-NaF has excellent pharmacokinetic properties (i.e. fast
blood clearance, urinary excretion, high uptake in regenerating
bone, minimal binding to serum proteins) and in 1972 was
approved by the US Food and Drug Administration for use as
a clinical PET tracer [122]. Although the studies discussed
above show that 18F-NaF is a suitable tracer for the detection
of (early) vascular microcalcifications, uptake of 18F-NaF in
these lesions is not specific, hampering elucidation of patholog-
ical molecular mechanisms. To define potential treatment tar-
gets based on underlying pathophysiological mechanisms, ra-
diotracers that specifically bind to vascular calcification-
specific biomarkers (i.e. receptors, enzymes, proteins) are nec-
essary. In addition, it is difficult to distinguish intimal from
medial calcification with noninvasive imaging techniques and
specific radiotracers are necessary to differentiate between these
two vascular calcification entities.
To investigate and decipher the underlying molecular
mechanisms that result in vascular calcification, design and
synthesis of smart diagnostic nuclear imaging probes is an
appropriate approach. Multimodality molecular imaging
now plays an important role in preclinical research as it com-
bines the strengths of different imaging modalities to elucidate
molecular basics of diseases, e.g. PET, single photon emission
tomography (SPECT), fluorescence, and contrast-enhanced
MRI. Specific imaging probes which combine optical imaging
with nuclear medicine imaging modalities (SPECT/CT and
PET/CT) are under development and enable additional
ex vivo tissue analysis using microscopy to analyse lesions
at the (sub)cellular level after a SPECT/CT or PET/CT scan.
These multimodal tracers will mainly be used in preclinical
imaging studies. There is also a role for these probes in clinical
studies during intraoperative surgery.
During recent decades, the utility of radiolabelled peptides
and proteins in preclinical and clinical research studies has
been proven. Solid-phase peptide synthesis (SPPS) is current-
ly the preferred technique for the production of synthetic pep-
tides and proteins. Chemical protein synthesis allows unlimit-
ed variation of the polypeptide chain by incorporation of non-
natural amino acids such as D-amino acids, and fluorescent or
affinity tags, chelators for metal ions or radioisotopes for use
in MRI, PET and SPECT, at single specific sites. Selective
proteinmodification at single sites cannot be achieved through
regular labelling of biologically obtained proteins. Current
optimized SPPS chemistry protocols enable effective peptide
synthesis of 30–50 amino acids. For the synthesis of peptides
and proteins larger than 30–50 amino acids, breakthrough
‘native chemical ligation’ (NCL) technologies have been de-
veloped that enable the formation of a peptide bond between
two unprotected peptides resulting in larger synthetic proteins
(50–200 amino acids) with a fully native peptide backbone
[123, 124]. NCL can also be used to efficiently introduce
labels into chemically synthesized proteins [125].
For site-specific conjugation of a multimodal label
(fluorophore and chelator; Fig. 4) to a protein, two strategies
Fig. 4 Left: Model of chemokine CCL5 synthesized by Boc-based SPPS
and NCL. An extra lysine residue was coupled at the C-terminus of
CCL5. Subsequently, a bimodal rhodamine/DTPA label was conjugated
through an oxime bond. Right: Confocal microscopy imaging of mouse
bone marrow derived macrophages (BMMs) and 3T3 fibroblasts. a DIC
contrast image of BMMs; bMerged image of BMMs stainedwith CCL5–
rhodamine/DTPA (1,500 nM) and with SYTO13 (2 μM; nuclei staining);
c DIC contrast image of 3T3 fibroblasts; d Merged image of 3T3
fibroblasts stained with CCL5–rhodamine/DTPA (1,500 nM) and
SYTO13 (2 μM)
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have been designed and optimized by our research group. One
strategy uses a thiaproline residue appended to a lysine
sidechain (Lys[Thz]), as an unlockable thiol handle that en-
ables orthogonal modification of prefolded proteins [126].
This method is compatible with Boc-based SPPS, NCL, and
standard methods for disulfide bridge formation. The other
strategy is based on aniline-catalysed oxime bond formation
[127]. Oxime ligations comprise chemoselective mild reac-
tions of a ketone or aldehyde with an aminooxy to form ox-
imes which are stable at neutral pH [128]. Because the widely
used levulinoyl ketone group undergoes intramolecular
rearrangement, a novel oxime ligation strategy has been
developed with 3-(2-oxopropyl)-benzoic acid as a ketone
moiety that appears to give higher oxime ligation rates and
yields [129].
The techniques described above are used and will be used
to synthesize and radiolabel (multimodal) peptide-based mo-
lecular imaging agents. An interesting biomarker of vascular
calcification is matrix Gla protein (MGP; Fig. 5) [16]. This
protein consists of 84 amino acids and requires vitamin K-
dependent gamma-carboxylation for its function [130]. It is
mainly expressed by chondrocytes, VSMCs, endothelial cells
and fibroblasts. MGP binds calcium crystals, inhibits crystal
growth and plays a role in preventing osteoblastic differentia-
tion of normal VSMCs [131, 132]. As MGP binds calcium
crystals, it may be a suitable molecular imaging probe for the
investigation of early vascular calcium deposits. Moreover,
s i n c e unc a r boxy l a t e d MGP seems t o p r e c ed e
microcalcification, detection of inactive MGP might be an
interesting alternative [2, 133].
Another interesting biomarker in vascular calcification is
bone morphogenetic protein-2 (BMP-2). BMP-2 is a 114 ami-
no acid protein which transforms undifferentiated cells and
subpopulations of VSMCs into bone-forming cells [134,
135]. BMP also binds calcium crystals and thus can be used
as a molecular imaging probe. Osteocalcin (OC) is another
vitamin K-dependent protein that can be used as a molecular
Fig. 5 Vitamin K metabolism in the secretion of vitamin K-dependent
MGP. Scheme of the vitamin K cycle: in the endoplasmic reticulum,
posttranslational modification of Glu to Gla residues via reduction of
vitamin K to the hydroquinone form (KH2). KH2 is oxidized to KO by
the enzyme GGCX thereby facilitating the carboxylation of ucMGP to
cMGP. The enzyme VKOR recycles KO back to K and KH2 so that
vitamin K can be used some 1,000 times. VKA inhibits VKOR and
thus the recycling of vitamin K. This causes a vitamin K deficiency
with subsequent ucMGP formation. UcMGP is inactive thereby
allowing the formation of microcalcifications
Fig. 6 Different types of vascular
calcification can occur in the
vasculature. Vascular calcification
is clinically measured by CT and
represents the amount of vascular
burden. Moreover, calcification
detected on CT in the media
relates to vascular stiffness.
However, microcalcification
cannot be visualized by CT and
these early stages of calcification
can now be detected by 18F-NaF
PET. Microcalcifications are
responsible for destabilizing the
plaque, causing an increased risk
of plaque rupture. They also cause
vascular remodelling when
present in the vascular media. The
measurement of inactive MGP as
a marker of increased risk of the
formation of microcalcifications
is currently under development
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imaging probe for vulnerable plaque [136]. This 49 amino
acid protein inhibits calcium salt precipitation in vitro [137]
and is strongly upregulated in advanced atherosclerotic
lesions [138].
As well as the proteins discussed above, there are other
promising imaging probe candidates. Antibodies or preferably
antibody fragments that specifically bind to these proteins are
of great interest for the development of suitable tracers for
molecular imaging of molecular processes early in the initia-
tion of microcalcification. Moreover, peptides and proteins
that bind to receptors, enzymes or proteins that are upregulat-
ed during vascular calcification are promising candidates. The
development of new imaging agents requires a multistep
approach, including target selection, organic synthesis of
molecular imaging agents, optimization of target affinity
and pharmacokinetic profile of the tracer, and preclinical
evaluation.
Conclusion
Atherosclerosis is a multifactorial process that involves
both local and systemic processes. The vulnerable athero-
sclerotic plaque cannot simply be detected by plaque size,
and thus identification of molecular and cellular processes
underlying plaque vulnerability is crucial for diagnosis
and treatment (Fig. 6). Recent progress in imaging has
improved detection of atherosclerotic lesions and has led
to the ability to screen for vulnerable atherosclerotic
plaques. Combining expertise in biology, chemistry, nu-
clear medicine and cardiology will advance our under-
standing of critical determinants of the high-risk plaque
and result in tailor-made imaging radiotracers to differen-
tiate the vulnerable plaque. Ultimately, this strategy will
open novel avenues for diagnosis and treatment of the
patient with high-risk disease.
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